NasdaqGS:MDGLBiotechs
Madrigal Expands Beyond Rezdiffra With New RNA Licensing Deal
Madrigal Pharmaceuticals (NasdaqGS:MDGL) has entered an exclusive global licensing agreement with Suzhou Ribo Life Science and Ribocure.
The deal covers six preclinical small interfering RNA programs and extends Madrigal's pipeline beyond its MASH therapy Rezdiffra.
The companies expect to submit investigational new drug applications for the first siRNA candidates this year.
Madrigal Pharmaceuticals is drawing fresh attention as it adds RNA based therapies to a portfolio that already...